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Abstract
LPS-activated neutrophils secrete IL-1b by activation of TLR-4. Based on studies in macrophages, it is likely that ROS and
lysosomal destabilization regulated by Syk activation may also be involved. Since neutrophils have abundant expression of
the ITIM-containing co-receptor CEACAM1 and Gram-negative bacteria such as Neisseria utilize CEACAM1 as a receptor that
inhibits inflammation, we hypothesized that the overall production of IL-1b in LPS treated neutrophils may be negatively
regulated by CEACAM1. We found that LPS treated neutrophils induced phosphorylation of Syk resulting in the formation of
a complex including TLR4, p-Syk, and p-CEACAM1, which in turn, recruited the inhibitory phosphatase SHP-1. LPS treatment
leads to ROS production, lysosomal damage, caspase-1 activation and IL-1b secretion in neutrophils. The absence of this
regulation in Ceacam1
2/2 neutrophils led to hyper production of IL-1b in response to LPS. The hyper production of IL-1b
was abrogated by in vivo reconstitution of wild type but not ITIM-mutated CEACAM1 bone marrow stem cells. Blocking Syk
activation by kinase inhibitors or RNAi reduced Syk phosphorylation, lysosomal destabilization, ROS production, and
caspase-1 activation in Ceacam1
2/2 neutrophils. We conclude that LPS treatment of neutrophils triggers formation of a
complex of TLR4 with pSyk and pCEACAM1, which upon recruitment of SHP-1 to the ITIMs of pCEACAM1, inhibits IL-1b
production by the inflammasome. Thus, CEACAM1 fine-tunes IL-1b production in LPS treated neutrophils, explaining why
the additional utilization of CEACAM1 as a pathogen receptor would further inhibit inflammation.
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Introduction
Neutrophils, the most abundant leukocytes, respond to and help
mediate inflammation by production of chemokines and cytokines,
including IL-1b. While much is know about their migration to and
activation at the site of inflammation, much less is known about
the regulation of their inflammatory responses once they arrive.
Importantly, CEACAM1, an ITIM-containing, abundantly ex-
pressed receptor on neutrophils, is a frequently used receptor for
Gram-negative pathogens that results in an inhibition of the host
immune response [1,2]. Recently, we have shown that when
CEACAM1 is genetically ablated in mice, neutrophils are over-
produced and over-activated during infection with the model gram
positive pathogen, Listeria monocytogenes, resulting in accelerated
mortality [3]. We hypothesized that elevated production of IL-1b
(2-3-fold over wild type) in response to infection was a major cause
contributing to accelerated mortality and was likely attributable
directly to neutrophils lacking the inhibitory co-receptor CEA-
CAM1. In the case of Gram-negative Neisseria pathogens that bind
to CEACAM1, binding leads to both epithelial colonization and
inhibition of the inflammatory response [4]. The high levels of
CEACAM1 on neutrophils suggest that exposure to Gram-
negative bacteria would lead to a more general inhibitory
response, perhaps through the TLR4 pathway in response to
LPS. In order to test this hypothesis in a model system, we have
directly analyzed the production of IL-1b from LPS treated wild
type versus Ceacam1
2/2 neutrophils. LPS was chosen as a well-
defined ligand for TLR4 signaling and for its action on neutrophils
as a single agent.
IL-1b belongs to the IL-1 cytokine family and is associated with
many inflammatory responses and autoinflammatory diseases [5–
11]. Pathogen-associated molecular patterns (PAMPs) activate
Toll-like-receptors (TLRs) and NF-kB signaling dependent
transcription, resulting in the transcription of the IL-1b precursor,
pro-IL-1b. The maturation of IL-1b is regulated by the
inflammasome, a multi-molecular complex composed of pro-
caspase-1, Apoptosis-associated Speck-Like Protein (ASC), and
NOD like receptor (NLR) family members, including NLRP1
(NOD like receptor containing pyrin 1), NLRP3 and NLRC4
(NOD like receptor containing CARD) [7–8,12–13]. The fully
assembled inflammasome converts pro-caspase-1 into its enzymat-
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[7,8,13].
LPS is an endotoxin recognized by pattern recognition receptor
TLR4 in myeloid cells, including macrophages and neutrophils,
that induces an inflammatory response. LPS triggers the
production of pro-IL-1b through the TLR-4-NF-kB pathway in
macrophages and neutrophils [14]. Since LPS alone cannot
activate the maturation of IL-1b in macrophages, IL-1b
production in response to LPS treatment is minimal [14].
Macrophages require second signals such as ATP or crystals to
activate the NLR family proteins [13]. In contrast, LPS alone can
induce high levels of mature IL-1b in neutrophils [15]. Thus, the
mechanism of LPS induced IL-1b production in neutrophils must
differ from macrophages in some fundamental manner. Since
caspase-1 deficient neutrophils fail to produce mature IL-1b upon
stimulation with LPS, it is likely that the caspase-1 dependent
inflammasome NLRP3 is downstream from TLR4 [15], but the
detailed mechanism from TLR4 to the inflammasome is largely
unknown.
In a recent study of the differential expression of NLRP3 among
hematopoeitic cells, it was shown that neutrophils express similar
levels of NLRP3 as resting macrophages, and the expression of
NLRP3 is significantly increased in neutrophils in response to
treatment with TLR ligands, including LPS [16]. The expression
of ASC, another component of inflammasomes, is also upregulated
in neutrophils by inflammation [17]. Since an inflammatory
stimulus like LPS may activate the NLRP3 inflammasome in
neutrophils, it is of interest to determine the mechanism of its
regulation.
Cellular signals including ATP triggered induction of pore
formation, K
+ efflux, ROS production and lysosomal destabiliza-
tion have been shown to induce NLRP3 inflammasome assembly,
procaspase-1 cleavage, pro- IL-1b cleavage and IL-1b secretion in
macrophages [5,7,9,13,18–19]. Although the molecular mecha-
nisms of NLRP3 inflammasome activation and IL-1b secretion are
still being defined, recent studies identified an upstream kinase,
spleen tyrosine kinase (Syk) as a critical mediator [5,20–21].
Indeed, Syk regulates both ROS production [5,21,22,23] and
lysosomal activity [20,24–25], two major signals for NLRP3
inflammasome activation in macrophages [7,9,13,19]. For exam-
ple, Syk couples the NLRP3 inflammasome activation in
macrophages in response to fungi and crystals [5,20]. Syk is a
non-receptor kinase usually recruited and activated by ITAM
containing receptors, such as the Ig-a/b B cell receptor and FcRc
[21]. However, Syk also associates with receptors in an ITAM-
independent manner [21]. In response to stimulation by TLR
ligands, Syk is phosphorylated and associates with TLRs, including
TLR4 and TLR9, [26–28]. Furthermore, Syk inhibitors attenuate
TLR downstream signaling pathways [26–28]. In the case of
human neutrophils, TLR4 directly associates with Syk and LPS
stimulation increases this association [28]. Similar to neutrophils,
Syk constitutively associates with TLR4 and Myd88 in human
monocytes, and p-Syk associates with TLR4 after LPS treatment
[29]. Although these studies place Syk in a critical downstream
position associated with TLR4 signaling, they do not answer the
question if activation of Syk through LPS-TLR4 leads to caspase-1
activation, ROS production, lysosomal damage and IL-1b
production in neutrophils. Furthermore, since phosphorylated
Syk can, in turn, be regulated by inhibitory phosphatases such as
SHP1/2 [21], it is of special interest to identify co-receptors
responsible for the recruitment of these inhibitory phosphatases.
In this respect, CEACAM1 (CD66a) serves as a likely candidate
based on its role as a co-inhibitory molecule in the immune system
[1,30–36] and its abundant expression in neutrophils [3].
CEACAM1 is composed of a variable number of Ig-like
extracellular domains, a trans-membrane domain and either long
or short cytoplasmic domains [30]. There are 4 murine
CEACAM1 isoforms, CEACAM1-2L, CEACAM1-2S, CEA-
CAM1-4L and CEACAM1-4S based on the number of extracel-
lular Ig-like domains and the length of the cytoplasmic tail [30].
CEACAM1 short cytoplasmic domains primarily interact with the
actin-cytoskeleton [37–38], while the long cytoplasmic domains in
addition contain two immuno-tyrosine based inhibitory motifs
(ITIMs), which upon phosphorylation recruit Src homology 2
domain-containing phosphatases (SHP-1/2) [30]. Notably, re-
cruitment of SHP-1 by the CEACAM1 long form inhibits T cell
activation through dephosphorylation of Zap-70, a Syk family
kinase member [33]. However, the role of CEACAM1-SHP-1
modulation of Syk activation in other immune cells and its
downstream effects has been little studied.
We report here that LPS alone activates the caspase-1
inflammasome in neutrophils. LPS treated neutrophils require
ROS production and lysosomal destabilization to activate the
NLRP3 inflammasome, which in turn, is coupled to Syk
activation. LPS triggers Syk phosphorylation and an association
between p-Syk and TLR4. LPS stimulation also leads to
phosphorylation of CEACAM1 on its ITIMs, followed by
recruitment of SHP-1 and incorporation into the TLR4-p-Syk
complex. As expected, the recruitment of SHP-1 leads to
attenuated Syk activation. Ceacam1
2/2 neutrophils exhibit
elevated Syk activation, leading to augmented ROS production
and lysosomal destabilization, along with caspase-1 activation and
IL-1b production. Reintroduction of different CEACAM1 iso-
forms into Ceacam1
2/2 neutrophils demonstrates that the
inhibition provided by CEACAM1 depends on the ITIMs in
CEACAM1 long form and the recruitment of SHP-1. Blocking
Syk activation by the inhibitor piceatannol or reduction of Syk
amounts by RNAi significantly down-regulated NLRP3 inflam-
masome activation in Ceacam1
2/2 neutrophils, normalizing their
IL-1b production. Therefore, our results indicate that CEACAM1
acts as a critical checkpoint in the regulation of Syk coupled
Author Summary
Pathogens often evade the immune system by directly
binding to and inhibiting neutrophils, abundant white cells
that accumulate at the site of infection. For example Gram-
negative Neisseria pathogens, such as those that cause
gonorrhea or meningitis, bind the neutrophil receptor
CEACAM1. Gram-negative bacteria express lipopolysaccha-
ride (LPS) that interacts with toll-like receptor-4 (TLR4) on
neutrophils. Since CEACAM1 is an inhibitory receptor, we
hypothesized that LPS activation of TLR4 would be
inhibited. In this paper we show that this is the case and
that the mechanism of LPS inhibition involves induction of
a complex between the LPS receptor TLR4, CEACAM1 and
an activating kinase called Syk. In the presence of
CEACAM1, an inhibitory phosphatase (opposes the kinase)
is recruited to the complex that prevents the activation of
Syk. The net effect is the inhibition of the pathway that
normally leads to the production of the pro-inflammatory
cytokine IL-1b. We show that this inhibition is lost in
CEACAM1 deficient neutrophils leading to hyper produc-
tion of IL-1b. We think that CEACAM1 fine-tunes the
normal inflammatory response at the site of infection
preventing hyper-inflammation, but in the case of Gram-
negative pathogens that actually bind to neutrophils,
inflammation is further blunted, favoring the infectious
process.
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production in neutrophils. The importance of the negative
regulation of the inflammasome in neutrophils may be related to
their abundant accumulation at the site of infection, where the
amount of IL-1b release may need to be finely controlled. Yet, the
fact that they highly express the components of the inflammasome
suggests that they are capable of generating rather large amounts
of IL-1b, which may contribute to runaway inflammation in the
case of sepsis or diseases such as inflammatory bowel disease where
neutrophils predominate and are activated by bacterial products
such as LPS. Finally, the fact that potent pathogens such as
Neisseria are able to suppress inflammation is likely due to the use of
CEACAM1 as a receptor and its role in the regulation IL-1b
production.
Results
LPS induced inflammasome activation in neutrophils
depends on ROS production and lysosomal
destabilization
Since previous studies show LPS alone is sufficient for
neutrophil IL-1b production, we were interested in determining
whether the caspase-1 inflammasome is activated and the
mechanisms for its activation. Consistent with previous studies,
LPS alone activated IL-1b production in neutrophils (Figure 1A–
B), but not in macrophages that required the additional signals
ATP or alum crystals (Figure S1A). Since ATP and potassium
efflux have been implicated in the secretion of IL-1b in
macrophages [18], we treated LPS primed neutrophils with
KN62, an antagonist of the P2X7 receptor, the receptor largely
responsible for mediating these ATP effects [39]. Although we did
observe ATP release from LPS treated neutrophils (Figure S1B),
KN62 failed to block caspase-1 activation or IL-1b production
(Figure 1A–B). Furthermore, LPS fully stimulated IL-1b
production in P2X7 deficient neutrophils (Figure 1A–B),
confirming the dispensability of exogenous ATP for LPS induced
IL-1b production. We also examined the role of K
+ efflux by
blocking potassium channels with glibenclamide [5], a treatment
that showed no measureable reduction of IL-1b production (data
not shown), excluding the involvement of K
+ efflux in neutrophil
LPS induced inflammasome activation. To test whether ROS
production was necessary for inflammasome activation in
neutrophils, we treated WT neutrophils with (2R, 4R)-4-
aminopyrrolidine-2, 4-dicarboxylate (APDC), an inhibitor of
NADPH-oxidase-dependent ROS production [5]. Indeed, APDC
inhibited LPS stimulated ROS production in neutrophils by 70%
(Figure 1C), and IL-1b production by 45% (Figure 1A–B). To
further test the role of ROS production on the inflammasome,
neutrophils from gp91phox-deficient (Cybb
2/2) mice [19] were
treated with LPS. In these neutrophils less caspase-1 activation and
IL-1b production were observed (Figure 1A–B), indicating that
ROS production significantly mediates neutrophil inflammasome
activation. Lysosomal destabilization commonly refers to both the
release of cathepsin B and the inability of the lysosomal
compartment to retain a low pH necessary for its lytic activities.
When neutrophil lysosomal acidification was inhibited with
bafilomycin A [5,19], caspase-1 activation and IL-1b secretion
were significantly reduced (Figure 1A–B), demonstrating the
critical role of lysosomal destabilization. Besides showing that
caspase-1 was activated in LPS treated neutrophils, we also
blocked caspase-1 activation using the caspase-1 inhibitor z-
YVAD-fmk [5,19], resulting in reduced caspase-1 activation and
IL-1b production (Figure 1A–B), and suggesting that the caspase-
1 containing inflammasome is mainly responsible for neutrophil
IL-1b production. We conclude that LPS induced ROS
production and lysosomal destabilization, which in turn, activated
the inflammasome in neutrophils.
LPS induced inflammasome activation is coupled to Syk
activation in neutrophils
Since Syk regulates macrophage inflammasome activation by
modulation of ROS production and lysosomal destabilization
[5,20–21], we asked if Syk is similarly coupled to LPS triggered
neutrophil inflammasome activation. LPS induced Syk phosphor-
ylation (p-Syk 525/526) in neutrophils was down regulated in a
dose dependent manner by piceatannol (Figure 2A), a specific
Syk inhibitor [20,26]. Piceatannol also decreased LPS triggered
neutrophil ROS production (Figure 2B) as shown by reduction of
mean fluorescence intensity (MFI) of the ROS sensitive fluorescent
probe 2979-dichlorofluorescin diacetate (H2DCFDA) [5] and
Figure 1. LPS induced neutrophil inflammasome activation
depends on ROS production and lysosome destabilization. (A)
IL-1b production in the supernatants of wild type (WT), P2X7
2/2 and
Cybb
2/2 neutrophils under different treatment conditions: LPS
(100 ng/ml), KN62 (2 mM, neutrophils were pre-treated for 30 minutes
before LPS treatment), APDC (100 mM), bafilomycin A (125 nM), z-YVAD-
fmk (1 mM). (B) Immunoblot analysis showing caspase-1 activation of
WT, P2X7
2/2 and Cybb
2/2 neutrophils under different treatment
conditions. (C) ROS production by LPS treated WT and CEACAM1
2/2
neutrophils with or without APDC (100 mM) as measured by MFI of
fluorescent probe H2DCFDA using FACS. Data are representative of 3
different experiments (B) and p values (A and C) were calculated by a 2-
tailed T-test, **0.001,p#0.01 ,***p#0.001.
doi:10.1371/journal.ppat.1002597.g001
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LysoSensor Green (Figure 2C), a pH-sensitive dye which
fluoresces only after encountering acidic environments [19].
Correspondingly, piceatannol treatment also down-regulated
caspase-1 activation and IL-1b production (Figure 2D–E). Unlike
crystal induced lysosomal destabilization in macrophages, which
requires phagocytosis [9,19–20], LPS triggered lysosomal destabi-
lization in neutrophils was phagocytosis independent, because
treatment of neutrophils with the phagocytosis inhibitor cytocha-
lasin D, did not affect LPS triggered lysosomal destabilization or
capase-1 activation (data not shown). Thus, neutrophils, the most
abundant subset of granulocytes, require Syk, ROS, and lysosomal
destabilization as a general inflammasome activation mechanism
in response to LPS.
Genetic ablation of CEACAM1 leads to elevated p-Syk
and inflammasome activation in neutrophils
Since Syk positively regulates LPS induced inflammasome
activation in neutrophils, it is of interest to study the regulatory
mechanism of Syk activation. CEACAM1 is a likely candidate due
to its high expression in neutrophils and since CEACAM1 was
shown to negatively regulate the related kinase Zap-70 in activated
T cells [33]. We hypothesized that neutrophils lacking CEACAM1
would have unregulated Syk mediated inflammasome activation
Figure 2. Syk activation is coupled to LPS induced neutrophil inflammasome activation. (A) Immunoblot analysis of p-Syk (Y525/526), Syk
and GAPDH of neutrophils before and after LPS treatment (100 ng/ml) in the presence of the Syk inhibitor piceatannol. (B) ROS production by LPS
treated neutrophils with or without piceatannol treatment (0.5 mM) as measured by MFI of fluorescent probe H2DCFDA using FACS. (C)
Quantification of lysosome destabilization of neutrophils with or without piceatannol treatment (0.5 mM) as measured by MFI of LysoSensor Green
using FACS. (D) IL-1b production in the supernatants of LPS treated WT neutrophils with or without piceatannol treatment. (E) Immunoblot analysis
showing caspase-1 activation of LPS treated neutrophils with or without piceatannol treatment. Data are representative of 3 different experiments (A
and E) and p values (D and E) were calculated by a 2-tailed T-test *0.01,p#0.05,**0.001,p#0.01,***p#0.001.
doi:10.1371/journal.ppat.1002597.g002
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CEACAM1 led to dramatically higher levels of p-Syk in
Ceacam1
2/2 neutrophils compared with WT neutrophils
(Figure 3A). We also compared global tyrosine phosphorylation
for WT versus Ceacam1
2/2 neutrophils after stimulation with
LPS and found no obvious differences (data not shown),
demonstrating that it is important to look at kinases using
phosphotyrosine specific antibodies. To study the mechanism of
the activation of Syk, we performed immunoprecipitation (IP)
studies with neutrophils from Ceacam1
2/2 and WT mice. While
Syk was co-IPed with TLR4 before and after treatment with LPS,
pSyk co-IPed with Syk and TLR4 only in response to LPS
treatment and this association increased in Ceacam1
2/2 com-
pared to wild type neutrophils (Figure 3B). We also IPed TLR4
and tested its association with Dectin, a lectin associated with an
ITAM response to bacteria with engagement of Syk [23,40]. We
found that LPS stimulation did not trigger the association of
Dectin to the TLR4 complex (data not shown). Thus, LPS is a
specific trigger of Syk activation, and the activated form remains
associated with TLR4. Furthermore, when TLR4 was IPed after
LPS treatment, the inhibitory co-receptor CEACAM1 was found
associated with TLR4 (Figure 3B). Thus, both CEACAM1 and
pSyk only associate with TLR4 when activated by LPS. The
mechanism by which CEACAM1 negatively regulates p-Syk in
this complex will be explored later (see below). In addition, a
previous study has shown that CD16/32 is not involved with LPS-
stimulated TLR4 signals in neutrophils [41]. As a negative control,
we IPed CD16/32 followed by immunoblotting with 4G10 on WT
vs Ceacam1
2/2 neutrophils after LPS stimulation and found a
small amount of activation of this ITAM containing FcR, but to
the same degree in WT and Ceacam1
2/2 neutrophils (data not
shown).
Elevated Syk activation was associated with enhanced ROS
production and was greatest for LPS treated Ceacam1
2/2
neutrophils (Figure 1C). In addition, elevated p-Syk correlated
with augmented lysosomal destabilization in Ceacam1
2/2 neu-
trophils. To demonstrate this on isolated cells, WT and
Ceacam1
2/2 neutrophils were incubated with DQ ovalbumin, a
lysosomal uptake marker, [19] with or without LPS. As expected,
DQ ovalbumin was restricted to lysosomes in resting stage WT
and Ceacam1
2/2 neutrophils (Figure 3C), but spread into the
cytosol upon lysosomal rupture in LPS treated neutrophils
(Figure 3C). Moreover, this effect was greatest in Ceacam1
2/2
neutrophils due to enhanced inflammasome activation. To
quantify lysosomal destabilization, neutrophils were stained with
acridine orange, a fluorescent dye that is highly fluorescent in
environmentally acidic lysosomes but is shifted to lower fluores-
cence in disrupted lysosomes [19]. As expected, we observed a
higher percentage of a lower fluorescent peak in Ceacam1
2/2
neutrophils versus WT neutrophils after LPS treatment (Figure
S2). Consistently, the increased MFI of the LysoSensor Green dye
in Ceacam1
2/2 neutrophils confirmed augmented lysosomal
destabilization in these cells compared to WT cells (Figure 3D).
Due to augmented ROS production and lysosomal destabilization,
Ceacam1
2/2 neutrophils exhibited significantly more IL-1b
production (7 fold, Figure 3E) and caspase-1 activation
(Figure 3F) upon LPS treatment compared to WT neutrophils.
Gibenlamide, also known as glyburide, an inhibitor of the NLRP3
inflammasome, blocked IL-1ß production in both WT and
CEACAM1 deficient neutrophils. (Figure 3G). These data
demonstrate that the production of IL-1ß in response to LPS is
through the NLRP3 inflammasome in neutrophils. Since genetic
or inhibitor studies may affect the apoptotic status of neutrophils,
we also stained the neutrophils with annexin V. The results of
annexin V staining indicate that apoptosis was minimal (,7%) in
both WT and Ceacam1
2/2 neutrophils before and after LPS
treatment (data not shown).
Although the increased IL-1b production in Ceacam1
2/2
neutrophils could be due to increased transcription of IL-1b, there
was no difference of IL-1b mRNA amounts in WT and
Ceacam1
2/2 neutrophils as measured by quantitative real-time
PCR (Figure S3A), indicating a similar degree of TLR-NF-kB
signaling in WT and Ceacam1
2/2 neutrophils. This result also
suggests that the elevated amounts of p-Syk were not caused by
enhanced TLR-NF-kB signaling. In addition, we tested whether
various IL-1b inhibitors affect the production of TNF-a, another
TLR-NF-kB dependent cytokine. We found no significant
difference in the levels of TNF-a among treatment with the
various inhibitors in both WT and Ceacam1
2/2 neutrophils.
(Figure S3B) Similar to WT neutrophils, Ceacam1
2/2 neutro-
phils also depended on ROS and lysosomal destabilization for
inflammasome activation since they responded similarly to WT
neutrophils to KN62, APDC and bafilomycin A as manifested by
caspase-1 activation and IL-1b production (Figure 3E–F). Unlike
murine neutrophils, murine macrophages only express moderate
amounts of CEACAM1 [3], and WT and Ceacam1
2/2 bone
marrow derived macrophages (BMDMs) secreted similar amounts
of IL-1b upon stimulation by LPS with ATP or Alum crystals
(Figure S1A), suggesting that the genetic ablation of CEACAM1
does not affect macrophage IL-1b production.
LPS triggered IL-1b production is partially dependent on
cathepsin B in WT and Ceacam1
2/2 neutrophils
Previous studies on murine macrophages stimulated by crystals
or hemozoin identified the lysosomal protease cathepsin B as an
activator of the NLRP3 inflammasome, since cathepsin B
inhibitors partially blocked activation [3,6,9,19–20]. To determine
if a similar mechanism may operate in LPS treated neutrophils, we
examined cathepsin B activity in WT and Ceacam1
2/2
neutrophils. LPS treated Ceacam1
2/2 neutrophils exhibited
significantly elevated cathepsin B activity compared to WT
neutrophils (Figure 4A), with higher amounts of cathepsin B in
the supernatant of Ceacam1
2/2 neutrophils (Figure 4B). More-
over, the cathepsin B inhibitor CA-074-Me partially blocked WT
and Ceacam1
2/2 neutrophil caspase-1 activation and IL-1b
production (Figure 4C–D). Although the mechanism of cathepsin
B mediated NLRP3 inflammasome activation is unclear, we may
conclude that LPS triggered cathepsin B release is at least partially
responsible for NLRP3 activation in neutrophils.
CEACAM1 down-regulates Syk activation through ITIM
phosphorylation and recruitment of SHP-1
CEACAM1 functions as a co-inhibitory receptor through
phosphorylation of its ITIMs and the recruitment of SHP-1
[1,3,30–35]. Above we showed that p-Syk is elevated in
Ceacam1
2/2 neutrophils upon LPS stimulation and that TLR4
is associated with both pSyk and CEACAM1 (Figure 3B),
suggesting that CEACAM1 is also a negative regulator of Syk
activation. Since the likely mechanism of inhibition involves
phosphorylation of CEACAM1’s ITIMs followed by recruitment
of SHP-1, we IPed CEACAM1 and performed immunoblot
analysis with anti-phosphotyrosine, anti-Syk and anti-SHP-1.
Significant tyrosine phosphorylation of CEACAM1 (Figure 5A)
and significant amounts of Syk were co-IPed in LPS treated WT
neutrophils (Figure 5A), thus indicating that CEACAM1 was
phosphorylated on its ITIMs and that Syk was physically
associated with CEACAM1 after LPS treatment. As predicted,
CEACAM1 Regulated IL-1b Production in Neutrophils
PLoS Pathogens | www.plospathogens.org 5 April 2012 | Volume 8 | Issue 4 | e1002597Figure 3. Loss of CEACAM1 leads to elevated Syk activation and enhanced inflammasome activation. (A)I m m u n o b l o ta n a l y s i so fW T
and Ceacam1
2/2 (KO) neutrophils with p-Syk (Y525/526), Syk and GAPDH antibodies. (B) Immunoblot analysis of TLR4, Syk, p-Syk and CEACAM1 in WT
and Ceacam1
2/2 (KO) neutrophils with or without LPS treatment (100 ng/ml) after immunoprecipitation with TLR4 antibody. (C) Confocal microscopy
showing LPS induced lysosomal destabilization in WT and Ceacam1
2/2 neutrophils (DQ-Ovalbumin, 10 mg/ml; green) with or without LPS (100 ng/ml),
cell membranes were stained with fluorescent cholera toxin B-subunit (red). (D) Quantification of lysosomal destabilization of WT and Ceacam1
2/2
neutrophils asmeasuredbyMFIofLysoSensorGreenusingFACS.(E)IL -1 bproductionin thesupernatantsofLPStreatedWTandCeacam1
2/2 neutrophils
under different treatment conditions. (F) Immunoblot analysis showing caspase-1 activation of LPS treated WT and Ceacam1
2/2 neutrophils under
different treatment conditions.(G)I L - 1 b production inthesupernatants ofLPS treatedWTneutrophilswithorwithout glibenclamidetreatment(250 mM).
Data are representative of 3 different experiments and p values (C) were calculated by a 2-tailed T-test *0.01,p#0.05,**0.001,p#0.01,***p#0.001.
doi:10.1371/journal.ppat.1002597.g003
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dependent manner (Figure 5A). Furthermore, when SHP-1 was
IPed, it was recruited more strongly to LPS treated WT rather
than Ceacam1
2/2 neutrophils (Figure 5B), in agreement with
the expectation that association of SHP-1 with Syk is enhanced in
WT neutrophils when CEACAM1 is present.
To prove that the inhibition provided by CEACAM1 in vivo
relies on phosphorylation of its ITIMs and SHP-1 recruitment, we
reintroduced CEACAM1-2L, CEACAM1-4L, CEACAM1-2S,
CEACAM1-4S, ITIM mutated CEACAM1-2L (CEACAM1-
2Lm) and ITIM mutated CEACAM1-4L (CEACAM1-4Lm) into
Ceacam1
2/2 bone marrow stem cells using GFP containing
retroviral vectors, and then injected GFP positive cells back into
lethally irradiated Ceacam1
2/2 recipients. Two months later, we
isolated neutrophils and examined their phenotypes (scheme
shown in Figure S4). We found that compared to neutrophils
recovered from mice reconstituted with empty vectors transduced
Ceacam1
2/2 bone marrow stem cells, p-Syk amounts were
reduced in neutrophils receiving CEACAM1 long isoforms, but
not in those receiving the short isoforms (Figure 5C). Further-
more, this down-regulation was abrogated by mutation of the
ITIMs in CEACAM1 long isoforms (Figure 5C). Consistently,
only CEACAM1 long isoforms containing intact ITIMs were able
to associate with Syk as shown by IP analysis with CEACAM1
antibody (Figure 5D). As expected, the down-regulation of Syk
activation by restoration of CEACAM1 long isoforms in
Ceacam1
2/2 neutrophils attenuated ROS production and
lysosomal destabilization (data not shown), leading to reduced
IL-1b production and caspase-1 activation (Figure 5E–F).
These results are similar to previous studies on T-cells in which
activation of T-cells led to induction of CEACAM1 [34] followed
by phosphorylation of CEACAM1 and recruitment of SHP-1,
which in turn, led to down activation of the Syk-related kinase
ZAP-70 [33]. The main difference is that CEACAM1 is
constitutively expressed in neutrophils, thus maintaining a
relatively low level of Syk mediated inflammasome activation
prior to and after LPS activation.
Reduction of SHP-1 amounts by RNAi leads to elevated
Syk activation and augmented inflammasome activation
To further confirm that CEACAM1 regulation of Syk mediated
inflammasome activation depends on SHP-1 recruitment, we
reduced the amount of endogenous SHP-1 with retroviral vectors
containing GFP and shRNA against SHP-1. We transduced WT
bone marrow stem cells with shRNA containing retroviral vectors
and injected GFP selected cells into lethally irradiated WT
recipients. We then recovered neutrophils after 2 months of bone
marrow reconstitution. Immunoblot analysis confirmed an
efficient reduction of SHP-1 mRNA amounts (Figure 6A), and
showed elevated Syk phosphorylation compared with neutrophils
isolated from WT mice reconstituted with control shRNA
retroviral vector transduced WT bone marrow stem cells
(Figure 6A). The elevated Syk activation correlated with
augmented neutrophil ROS production (Figure 6B) and
Figure 4. LPS triggered IL-1b production in WT and Ceacam1
2/2 neutrophils is partially dependent on cathepsin B. (A) Confocal
microscopy showing cathepsin B activity in LPS treated WT and Ceacam1
2/2 (KO) neutrophils. (B) Immunoblot analysis showing cathepsin B amounts
in the supernatants of LPS treated WT and Ceacam1
2/2 neutrophils. (C) IL-1b production in the supernatants of LPS treated WT and Ceacam1
2/2
neutrophils after treatment with CA-074-Me. (D) Immunoblot analysis showing caspase-1 activation of LPS treated WT and Ceacam1
2/2 neutrophils
after CA-074-Me treatment. Data are representative of 3 different experiments (A, B and D) and p values (C) were calculated by a 2-tailed T-test
***p#0.001.
doi:10.1371/journal.ppat.1002597.g004
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observed elevated caspase-1 activation and IL-1b production after
RNAi mediated reduction of SHP-1 amounts (Figure 6D–E).
These data demonstrate the indispensable role of SHP-1 in the
down-regulation of Syk coupled NLRP3 inflammasome activation
in neutrophils.
Src family kinase Lyn acts upstream of Syk and CEACAM1
Syk is usually activated by phosphorylation with a Src kinase
[21]. For example, Src family kinase Lyn phosphorylates Syk in
macrophages [20]. To determine if Lyn is associated with Syk in
neutrophils, we IPed Lyn and found that Syk was specifically
pulled down in LPS treated WT neutrophils (Figure S5A).
Figure 5. CEACAM1 down-regulates Syk activation through ITIM recruitment of SHP-1. (A) Immunoblot analysis of p-Tyr, Syk, SHP-1 and
CEACAM1 in WT and Ceacam1
2/2 (KO) neutrophils with or without LPS treatment (100 ng/ml) after IP with anti-CEACAM1 antibody. (B) Immunoblot
analysis of Syk, SHP-1 in WT and Ceacam1
2/2 neutrophils with or without LPS after IP with anti-SHP-1 antibody. (C) Immunoblot analysis of p-Syk, Syk
and GAPDH in neutrophils from Ceacam1
2/2 mice reintroduced with empty vector (KO/(emp)), CEACAM1-2L (KO/(CC1-2L)), CEACAM1-4L (KO/(CC1-
4L)), CEACAM1-2S (KO/(CC1-2S)), CEACAM1-4S (KO/(CC1-4S)), ITIMs mutated CEACAM1-2L (KO/(CC1-2 Lm)) and ITIMs mutated CEACAM1-4L (KO/
(CC1-4 Lm)) with or without LPS treatment. (D) Immunoblot analysis of the p-Tyr, Syk, SHP-1 and CEACAM1 in neutrophils from KO/(emp), KO/(CC1-
2L), KO/(CC1-4L), KO/(CC1-2S), KO/(CC1-4S), KO/(CC1-2 Lm) and KO/(CC1-4 Lm) chimeras after IP with CEACAM1 antibody. (E) IL-1b production in the
supernatants of LPS treated neutrophils from KO/(emp), KO/(CC1-2L), KO/(CC1-4L), KO/(CC1-2S), KO/(CC1-4S), KO/(CC1-2 Lm) and KO/(CC1-4 Lm)
chimeras. (F) Immunoblot analysis showing caspase-1 activation of LPS treated neutrophils KO/(emp), KO/(CC1-2L), KO/(CC1-4L), KO/(CC1-2S), KO/
(CC1-4S), KO/(CC1-2 Lm) and KO/(CC1-4 Lm) chimeras. Data are representative of 3 different experiments and p values (E) were calculated by a 2-
tailed T-test ***p#0.001.
doi:10.1371/journal.ppat.1002597.g005
Figure 6. RNAi reduction of SHP-1 leads to elevated Syk activation and augmented inflammasome activation. (A) Immunoblot analysis
of p-Syk, Syk, SHP-1 and GAPDH of LPS treated neutrophils from WT mice reconstituted with shRNA control retroviral vector transduced WT BM cells
(WT/(shcontrol)), WT mice reconstituted with shSHP-1 retroviral vector transduced WT BM cells (WT/(shSHP-1)) compared with WT mice. (B) ROS
production by LPS treated neutrophils from WT mice, WT/(shcontrol) and WT/(shSHP-1) chimera measured by MFI of fluorescent probe H2DCFDA using
FACS. (C) Quantification of lysosome destabilization of LPS treated neutrophils from WT mice, WT/(shcontrol) and WT/(shSHP-1) chimera measured by
MFIofLysoSensor GreenusingFACS.(D)Immunoblotanalysisshowingcapase-1activationofLPStreatedneutrophilsfromWTmice,WT/(shcontrol)and
WT/(shSHP-1). (E) IL-1b production of LPS treated neutrophils from WT mice, WT/(shcontrol) and WT/(shSHP-1) chimera. Data are representative of 3
different experiments (A and D) and p values (B, C and E) were calculated by a 2-tailed T-test *0.01,p#0.05,**0.001,p#0.01,***p#0.001.
doi:10.1371/journal.ppat.1002597.g006
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antibody (Figure S5A), suggesting that Lyn may phosphorylate
both Syk and CEACAM1 in LPS treated neutrophils. This result is
consistent with previous studies on human neutrophils in which
Lyn was shown to phosphorylate CEACAM1 [42]. In order to
further confirm that a Src kinase regulates Syk activation in
neutrophils, we treated LPS primed neutrophils with the Src
kinase inhibitor PP2, a treatment that blocked Syk phosphoryla-
tion in a dose dependent manner (Figure S5B). Correspondingly,
PP2 also significantly blocked LPS induced ROS production (data
not shown) and lysosomal destabilization (data not shown), as well
as the downstream caspase-1 activation and IL-1b production
(Figure S5C–D).
Blocking Syk activation or reduction of Syk amounts
leads to attenuated inflammasome activation and IL-1b
production in Ceacam1
2/2 neutrophils
To further test if elevated Syk activation is indeed responsible
for augmented inflammasome activation in Ceacam1
2/2 neutro-
phils, we inactivated Syk with a kinase inhibitor and reduced
endogenous Syk amounts by RNAi treatment with the expectation
of reducing inflammasome activation and IL-1b production
comparable to WT levels. Indeed, piceatannol treatment of LPS
stimulated Ceacam1
2/2 neutrophils blocked Syk phosphorylation
in a dose dependent manner (Figure 7A), and also dramatically
inhibited LPS induced ROS production (data not shown),
lysosomal damage (data not shown), caspase-1 activation
(Figure 7B) and IL-1b production (Figure 7C). Moreover,
reduction of Syk with RNAi normalized the amounts of p-Syk in
LPS stimulated Ceacam1
2/2 neutrophils to amounts comparable
to WT neutrophils (Figure 7A). As expected, this treatment
significantly attenuated the amount of ROS production
(Figure 7D), lysosomal damage (Figure 7E), caspase-1 activation
(Figure 7B) and IL-1b production (Figure 7C) in LPS stimulated
Ceacam1
2/2 neutrophils. We conclude that elevated Syk
activation was mechanistically responsible for increased inflam-
masome activation in Ceacam1
2/2 neutrophils because either
inhibition of Syk activation or reduction of endogenous Syk,
normalized caspase-1 activation and IL-1b production.
Discussion
CEACAM1 (CD66a) has long been used as a marker for
neutrophils due to its abundant expression and further up-
regulation during activation [43]. Since it is an ITIM-containing
type 1 transmembrane protein, its main functional role in
lymphocytes generates inhibitory signals [1,30]. The fact that
many pathogens, including Neisseria, utilize CEACAM1 as a
receptor on neutrophils results in a potent inhibition of the
inflammatory response [1,2,44]. Although the mechanism of the
inhibition has been studied at the level of CEACAM1’s ITIM
phosphorylation, the downstream effects on key components of the
inflammatory response such as the inflammasome have not been
studied. In fact, recent attention has turned to the role of
CEACAM3, an ITAM-containing member of the CEA gene
family, as the chief regulator of a positive inflammatory response
in Neisseria infected neutrophils [4]. Yet, the predominantly high
levels of CEACAM1 on neutrophils suggest that inhibition would
be the main outcome of LPS mediated gram-negative infections.
Thus, we speculated that the inhibition was mediated by the LPS
signaling pathway and not solely due to the direct binding of the
bacteria to CEACAM1 or CEACAM3. Notably, the CEACAM3
response has been directly linked to Syk activation, which
according to our findings would be inhibited by CECAM1
inhibition of the LPS-TLR4 pathway.
While inflammasome activation has been intensively studied in
macrophages [7–8,12–13,18–19], the possibility that similar
mechanisms apply to the more abundant neutrophils has not
been comprehensively explored. In contrast to macrophages which
need two signals to activate inflammasomes, in neutrophils, we
found that LPS alone not only induced the production of pro-IL-
1b, but also induced its processing to mature pro-IL-1b. We found
that LPS stimulated neutrophils utilized ROS production and
lysosomal destabilization as signals to activate the inflammasome.
LPS induced TLR4 and the Src kinase Lyn association with Syk, a
kinase previously found coupled to ROS production and lysosomal
damage in PAMP stimulated macrophages [9,19–20]. The
inhibitory co-receptor CEACAM1 was recruited to TLR4 after
LPS treatment of neutrophils and recruited SHP-1, that in turn,
inhibited Syk phosphorylation. As a result, Ceacam1
2/2 neutro-
phils exhibited enhanced Syk phosphorylation and elevated ROS
production and lysosomal damage in response to LPS. Corre-
spondingly, LPS treated neutrophils from Ceacam1
2/2 mice
showed elevated caspase-1 activation and IL-1b production,
demonstrating that CEACAM1 negatively regulates NLRP3
inflammasome activation.
The role of ROS in inflammasome activation has been recently
investigated [45,46]. Since both macrophages and neutrophils
utilize ROS to kill bacteria via activation of NADPH oxidase, it
was originally postulated that the source of ROS in macrophages
was NADPH oxidase [47]. However, subsequent studies showed
that gp91phox (a component of the NADPH oxidase complex)
deficient mice produced normal amounts of IL-1b in response to
various inflammasome activators [48]. When gp91phox deficient
(Cybb
2/2) neutrophils were treated with LPS in our study, IL-1b
production was reduced by 50% suggesting that, at least in
neutrophils, NADPH oxidase was an important, but not the sole
source of ROS. Further comparison between neutrophils and
macrophages are necessary to resolve these apparent differences.
Syk mediates inflammasome activation in macrophages by fungi
and crystals [5,20–21]. We found that activation of the
inflammasome by LPS in neutrophils provides a direct link
between activation of TLR4 and Syk. We also found that Src
kinase associated with Syk, and that blocking Src kinase activity
abrogated Syk activation, indicating that a Src kinase (Lyn) is
responsible for phosporylation of Syk. Although ITAM containing
receptors are responsible for the classical activation of Syk, Syk can
also be activated through ITAM-independent signals [21]. For
example, LPS and other TLR ligands activate Syk [26–28]. TLR4
interacts with Syk constitutively in neutrophils and peripheral
blood mononuclear cells, and upon LPS treatment, TLR4
associates with p-Syk [28–29]. The TLR4 cytoplasmic domain
has a putative motif, which upon phosphorylation, can be
recognized by the SH2 domain of Syk [28,49]. Our data in
murine neutrophils agree with previous studies in human
neutrophils that show that TLR4 associates with p-Syk upon
LPS treatment [28].
Although elevated amounts of p-Syk induced more ROS
production and lysosomal damage in Ceacam1
2/2 neutrophils,
they did not affect pro-IL-1b or TNF-a transcription which is a
distinct pathway dependent on TLR4-NFkB signaling. This result
is consistent with previous studies that show Syk activation is not
directly involved in TLR4-NF-kB signaling [50] since normal
amounts of TNF-a and IL-6 are induced by LPS treatment in
Syk
2/2 models [51]. However, Syk activation is critical for
production of TNF-a in response to C-type lectin mediated fungal
recognition in macrophages [5]. Thus, there may be a receptor
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to different PAMPs in respect to the role of Syk.
Similar to previous studies in T cells where CEACAM1
associates with Zap-70 after T cell activation [33], we also found
that CEACAM1 associated with the related kinase Syk in LPS
treated neutrophils. Since CEACAM1 functions as an ITIM-SHP-
1 dependent co-inhibitory receptor in various types of immune
cells [1,31–36], we tested whether CEACAM1 down-regulates
neutrophil inflammasome activation in an ITIM-SHP-1 depen-
dent manner in vivo by reintroducing different CEACAM1
isoforms into Ceacam1
2/2 mice. Consistent with this hypothesis,
we found that only CEACAM1 long isoforms restored normal Syk
Figure 7. Blocking Syk activation or reduction of Syk amounts significantly inhibits inflammasome activation in Ceacam1
2/2
neutrophils. (A) Left, immunoblot analysis of p-Syk, Syk, GAPDH of LPS treated Ceacam1
2/2 (KO) neutrophils with or without piceatannol; Right,
immunoblot analysis of p-Syk, Syk, GAPDH of LPS treated neutrophils from Ceacam1
2/2 mice reconstituted with shRNA control retroviral vector
transduced Ceacam1
2/2 BM cells (KO/(shcontrol)), CEACAM1
2/2 mice reconstituted with shSyk retroviral vector transduced Ceacam1
2/2 BM cells (KO/
(shSyk)) compared with KO mice. (B) Left, immunoblot analysis of caspase-1 activation of LPS treated CEACAM1
2/2 neutrophils with or without
piceatannol;right,immunoblotanalysisofcaspase-1activationofLPStreatedneutrophilsfromCeacam1
2/2mice,KO/(shcontrol)andKO/(shSyk)chimera.
(C) Left, IL-1b production of LPS treated neutrophils from Ceacam1
2/2 mice with or without piceatannol; right, IL-1b production of LPS treated
neutrophils from KO mice, KO/(shcontrol) and KO/(shSyk) chimera. (D) ROS productionbyLPS treated neutrophils fromCeacam1
2/2 mice, KO/(shcontrol)
and KO/(shSyk) chimera measured by MFI of fluorescent probe H2DCFDA using FACS. (E) Quantification of lysosome destabilization of LPS treated
neutrophils from Ceacam1
2/2 mice, KO/(shcontrol) and KO/(shSyk) chimera measured byMFI ofLysoSensor Green using FACS.Dataare representative of
3 different experiments (A and B) and p values (C, D and E) were calculated by a 2-tailed T-test *0.01,p#0.05,**0.001,p#0.01,***p#0.001.
doi:10.1371/journal.ppat.1002597.g007
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mutating the ITIMs of CEACAM1 long isoforms abrogated this
restoration. Also IP analysis using SHP-1 antibody pulled down
Syk in LPS treated WT and Ceacam1
2/2 neutrophils, indicating
that SHP-1 can directly dephosphorylate Syk. Notably, there was
still an association between SHP-1 and Syk in Ceacam1
2/2
neutrophils although this association was significantly reduced in
the absence of CEACAM1, indicating that other ITIM containing
receptors may also recruit SHP-1 and dephosphorylate Syk. The
dependency on SHP-1 was also demonstrated by RNAi mediated
reduction of endogenous SHP-1 in WT mice, a treatment that led
to enhanced p-Syk amounts, caspase-1 activation and IL-1b in
LPS treated neutrophils. These results are consistent with the
previous observation that SHP-1 deficient (moth-eaten) mice
produced more IL-1b in response to PAMPs compared to wild
type mice [52–53]. Our study is the first to identify CEACAM1 as
the key co-receptor responsible for recruitment of SHP-1 to Syk
followed by inhibition of the inflammasome.
Due to the higher numbers of neutrophils compared to
monocytes and macrophages in the bone marrow, there is a
greater requirement for negative regulation of the inflammasome
in response to inflammatory signals such as LPS. In agreement
with this idea, we found a ten-fold higher level of expression of
CEACAM1 in murine BM neutrophils compared to monocytes
and macrophages [3]. Thus, the levels of CEACAM1, as well as its
activation and recruitment to TLR4, may be major regulators of
the inflammasome in both neutrophils and monocytes.
In summary, our results demonstrate that LPS triggers TLR4-
Syk mediated inflammasome activation in neutrophils. In
addition, CEACAM1, an ITIM containing co-receptor, fine-tunes
the activation of the pro-inflammatory kinase Syk and its attendant
immune response in neutrophils (Figure 8). We have identified a
critical feedback loop provided by CEACAM1 that down-
regulates the inflammasome activation and IL-1b production in
neutrophils. This study suggests that manipulation of CEACAM1
inhibition may provide clinical applications for treatment of
dangerous IL-1b dependent inflammatory responses and auto-
inflammatory diseases. This study also reveals a mechanism by
which pathogens that utilize CEACAM1 as a receptor can inhibit
inflammation.
Materials and Methods
Mice
No human research was performed in this study. This study was
carried out in strict accordance with the recommendations of the
Guide for the Care and use of Laboratory Animals of the National
Institutes of Health. The protocol (number 08017) was approved
by the Institutional Animal Care and Use Committee (IACUC) of
the City of Hope, an AAALAC approved facility (assurance
number A3001-01). Ceacam1
2/2 mice were generously provided
by Nicole Beauchemin (McGill University, Montreal, Canada).
WT C57/B6 mice were purchased from National Cancer
Institute. P2X7
2/2 C57/B6 and Cybb
2/2 C57/B6 were
purchased from Jackson Laboratory. Mice 7–12 weeks old were
used for all the experiments.
Cell sorting and FACS analysis
Neutrophils were purified using antibody labeling and magnetic
beads depletion as described below. Briefly, total bone marrow
cells were flushed out using PBS plus 2% FBS. Red blood cells
were lysed using red blood cell lysis buffer, total cells labeled with
biotin conjugated anti-Ly-6C, anti-B220, anti-CD3, anti-Ter119,
anti-F4/80, anti-CD11c, anti-ICAM, anti-NK1.1 and anti-CD19,
washed and incubated with anti-biotin microbeads followed by
auto magnetic-activated cell sorting (AutoMACS). FACS analysis
for measuring ROS production and lysosome destabilization was
performed as previously described [5,19]. For measuring ROS
production, purified neutrophils were treated with LPS (Sigma,
catalogue No. L2880-10MG, impurities,3%) for indicated times
in the presence of fluorescent probe 2979-dichlorofluorescin
diacetate (H2DCFDA), cells were permeabilized (BD Cytofix/
Cytoperm) and MFI of FITC was measured as indicator of ROS
production. For measuring neutrophil lysosomal destabilization,
neutrophils were treated with LPS for 2 hours and then
LysoSensor was added immediately before FACS analysis.
Neutrophils were also incubated with acridine orange together
with LPS for 2 hours, and cells with loss of lysosomal function
were measured as loss of acridine orange staining (PE-Cy5
channel). The FACS were performed on FACS Canto II (BD
Biosciences)
Quantitative Real-time PCR
RNA extractions from neutrophils and BMPCs were performed
using Trizol (Invitrogen). Reverse transcription was performed
(QIAGEN) followed by real-time on Bio-Rad IQ5 Real-time
Detection system. IL-1b mRNA was detected using the following
primers: 59-CAGGCAGGCAGTATCACTCA-39 and 59-AGCT-
CATATGGGTCCGACAG-39. The IL-1b mRNA level was
normalized to HPRT expression using the following primers 59-
GCTGGTGAAAAGGACCTCT-39 and 59-CACAGGACTA-
GAACACCTGC-39. The amplification parameters were initiated
at 95uC for 5 min, then 95uC for 30 s, 57uC for 30 s, and 72uC for
30 s for 40 cycles, followed by 7 min at 72uC for the final
extension.
Confocal microscopy
To observe neutrophil lysosome destabilization, neutrophils
were incubated for 2 hours with DQ ovalbumin (10 mg/ml)
together with LPS (100 ng/ml), then cells were permeabilized and
stained with Alexa fluor 647 cholera toxin B-subunit for
30 minutes. Cathepsin B activity was measured using Cathepsin
B detection kit according to instructions (Enzo lifesciences).
Confocal microscopy was performed on LSM 510 Meta Inverted
2 Photon.
Construction and generation of retroviral vectors
XhoI and EcoRI restriction sites were generated at the 59 and 39
ends of CEACAM1-2L, 4L, 2S or 4S cDNAs using the following
primers: 59-GAGTCTCGAGATGGAGCTGGCCTCAGCA-
CATC-39 and 59-GAGTGAATTCTCACTTCTTTTTTACT-
TCTGAATAAAC-39, and subsequently cloned into retroviral
vector (MSCV-EGFP) which was kindly provided by Zuoming
Sun (Department of Immunology, Beckman Research Institute of
City of Hope). The ITIM mutations on CEACAM1-2L and 4L
were generated using QuikChange XL Site-Directed Mutagenesis
Kit (Stratagene) with the following primers: 59-CAAGGTGGAT-
GACGTCGCAGCCACTGTCCTGAACTTCAAT-39 and 59-
ATTGAAGTTCAGGACAGTGGCTGCGACGTCATCCAC-
CTTG-39 (for the first Tyr), and 59-CCTTCTTCTCCAAGAGC-
CACAGAAACAGTTGCTTCAGAAGTAAAAAAG-39 and 59-
CTTTTTTACTTCTGAAGCAACTGTTTCTGTGGCTCTT-
GGAGAAGAAGG-39 (for the second Tyr). The shSyk control
vector, shSyk vector (pGFP-V-RS) and ShSHP-1 vector (pGFP-V-
RS) were purchased from Origene, and the target sequence of
shSyk vector is 59-CTTTGTCGGTGGCTCACAACAG-
GAAGGCA-39, and the target sequence of shSHP-1 vector is
59-TTGTGCGTGAGAGTCTCAGCCAACCTGGT-39. All ret-
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For MSCV-EGFP based vectors, viral titers of the supernatants
from the stable virus-producing cells were determined in NIH 3T3
cells by FACS. Both Phoenix and NIH3T3 cell lines were kindly
provided by Dr. Zuoming Sun (city of Hope).
Retroviral transduction of bone marrow stems cells
5-FU (5 mg/mouse) was injected i.p. into Ceacam1
2/2 mice
and bone marrow stem cells were collected 5 days after injection.
Stem cells were expanded in 10% FBS DMEM medium plus
20 ng/ml IL-3, 50 ng/ml IL-6 and SCF for 24 hours, followed by
retroviral transductions. For selecting MLCV based empty vector,
CEACAM1-2L, 4L, 2S, 4S, 2 Lm and 4 Lm transduced cells,
GFP positive cells were sorted 48 to 72 hours after transduction.
For selecting MSCV based shRNA control vector, shSyk vector
and shSHP-1 vector, puromycin (1 ug/ml) resistant cells were
collected 7 days later after transduction. Collected cells were then
injected i.v. into lethally irradiated Ceacam1
2/2 or WT recipients
(1–5610
5 cells/mouse). Two months later, phenotypes of
neutrophils from reconstituted recipients were characterized.
Immunoblot and immunoprecipitation
For immunoblots, 5610
6 neutrophils with/without LPS treat-
ment (100 ng/ml) for 30 minutes to measure Syk phosphorylation,
and 2 hours for measuring caspase-1 activation. Cells were lysed
using RIPA buffer (Sigma) supplemented with 4 mM Na3VO4,
50 mM NaF and 1 mM PMSF. Total cell extracts were examined
by immunoblot using corresponding antibodies for specific
proteins as previously described [34]. Immuno-precipitation was
performed as previously described [34]. Briefly, 50610
6 neutro-
phils with/without LPS treatment (100 ng/ml) were lysed using
1% NP40 supplemented with 4 mM Na3VO4, 50 mM NaF and
1 mM PMSF, the total cell lysate was pre-cleared with isotype
control murine or rabbit IgG, and then anti-CEACAM1 or SHP-1
antibody was added and rotated at 4uC overnight. The next day,
protein G agarose was added and rotated at 4uC for 4 hours,
washed, and run on SDS gels for immunoblot analysis.
ELISA
Neutrophils were treated with or without LPS for 4 hours and
supernatants collected. BMDMs were treated with LPS for 4 hours
then with ATP (5 mM) or Alum (200 ug/ml) for 1 hour and
supernatants collected. TNF-a, IL-1b levels were measured with
ELISA kits according to manufacturers’ instructions (BioLegend).
Supporting Information
Figure S1 IL-1b from bone marrow derived macrophag-
es (BMDM) and ATP from neutrophils of WT and
Ceacam1
2/2 mice. (A) BMDM were treated as shown. (B)
ATP release from neutrophils over time.
(TIF)
Figure 8. Model for the inhibition of the inflammasome in neutrophils by CEACAM1. (A) LPS binds to TLR (the usual downstream effects
such as activation of NFkB are not shown for clarity). (B) The complex recruits and activates Syk (pSyk) which in the absence of CEACAM1 fully
activates the inflammasome that includes ROS production from the mitochondrion and cathepsin B from the lysosome. The activated inflammasome
converts pro-caspase-1 to active caspase-1, which in turn converts pro-IL-1b to active IL-1b.( C) In the presence of CEACAM1, both Syk and CEACAM1
are phosphorylated when LPS binds to TLR4. CEACAM1 recruits SHP1 via its phosphorylated ITIM. SHP1 dephosphorylates pSyk, reducing the
production of ROS and lysosome disruption, which in turn, reduces the activity of the inflammasome.
doi:10.1371/journal.ppat.1002597.g008
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Ceacam1
2/2 neutrophils with acridine orange. Loss of
lysosomal staining with acridine orange (excitation 488 nm,
emission 650–690 nm) shows increase of the lower fluorescent
peak after LPS treatment.
(TIF)
Figure S3 IL-1b mRNA levels and TNFa protein levels in
WT and Ceacam1
2/2 neutrophils. (A) IL-1b mRNA levels in
LPS treated neutrophils over time. (B) Protein levels of TNFa
from neutrophils treated as shown.
(TIF)
Figure S4 Experimental design for retroviral transduc-
tion and bone marrow reconstitution.
(TIF)
Figure S5 Src family kinase Lyn acts upstream of Syk
and CEACAM1. (A) Immunoblot analysis showing Syk,
CEACAM1 and Lyn in WT and KO neutrophils with or without
LPS treatment (100 ng/ml) after immunoprecipitation with anti-
Lyn antibody. (B) Immunoblot analysis showing p-Syk and Syk in
WT and KO neutrophils with LPS treatment. (C) ELISA analysis
showing IL-1 b production by LPS treated WT and KO
neutrophils with or without PP2 treatment. (D) Immunoblot
analysis showing caspase-1 activation of LPS treated WT and KO
neutrophils with or without PP2 treatment.
(TIF)
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